Engineering actin-resistant human DNase I for treatment of cystic fibrosis.

Human deoxyribonuclease I (DNase I), an enzyme recently approved for treatment of cystic fibrosis (CF), has been engineered to create two classes of mutants: actin-resistant variants, which still catalyze DNA hydrolysis but are no longer inhibited by globular actin (G-actin) and active site variants...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Proc Natl Acad Sci U S A
Principais autores:	Ulmer, J S, Herzka, A, Toy, K J, Baker, D L, Dodge, A H, Sinicropi, D, Shak, S, Lazarus, R A
Formato:	Artigo
Idioma:	Inglês
Publicado em:	National Academy of Sciences 1996
Assuntos:	Research Article
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC38651/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8710851/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.93.16.8225
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!